Affiliation:
1. Instituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91192, Mexico
Abstract
Alzheimer’s disease was described more than 100 years ago and despite the fact that several molecules are being tested for its treatment, which are in phase III trials, the disease continues to progress. The main problem is that these molecules function properly in healthy neurons, while neuronal pathology includes plasma membrane disruption, malfunction of various organelles, and hyperphosphorylation of Tau and amyloid plaques. The main objective of this article is the discussion of a neuronal restoration therapy, where molecules designed for the treatment of Alzheimer’s disease would probably be more effective, and the quality of life of people would be better.
Reference101 articles.
1. Alzheimer’s 100th anniversary of death and his contribution to a better understanding of Senile dementia;Engelhardt;Arq. Neuro-Psiquiatr.,2015
2. Molecular genetics of early-onset Alzheimer’s disease revisited;Cacace;Alzheimer’s Dement.,2016
3. Wisniewski, T. (2024, April 20). A New Perspective on Alzheimer’s Disease as a Brain Expression of a Complex Metabolic Disorder, Alzheimer’s Disease, Available online: https://www.ncbi.nlm.nih.gov/books/NBK552149/.
4. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk;Jansen;Nat. Genet.,2019
5. Alzheimer disease risk genes: 29 and counting;Bertram;Nat. Rev. Neurol.,2019